Skip to main content
Clinical Trials/NCT01544738
NCT01544738CompletedNot Applicable

Aponeurotic Stimulation Effect on Parkinson Bradykinesia

Université Libre de Bruxelles2 sites in 1 country11 target enrollmentStarted: November 2008Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
11
Locations
2
Primary Endpoint
3D kinematic movement parameters and upper limb muscles electromyographic activation

Study Overview

Brief Summary

Movement slowness (bradykinesia) is one of the main motor symptoms in Parkinson Disease (PD). Several studies have shown that patients with PD exhibit slowness because they are unable to modulate, in an optimal way, the velocity of voluntary motor acts not induced by external stimulation. Indeed, these patients have difficulties to integrate multi-sensorial information, mainly proprioception.

The investigators investigated changes in shoulder velocity during pointing movements by patients with PD after stimulation of soft tissues (aponeurosis) of upper limb muscles. The stimulation consisted of manipulating, with a hook (the diacutaneous fibrolysis method), the aponeurotic tissues enrobing the heads of the upper limb muscles. This technique has previously been shown to decrease passive tension and the tendon reflex response of the manipulated muscle group. The investigators hypothesis is that aponeurotic manipulation of shoulder muscles therefore creates a modification in the proprioceptive information, which in return temporarily decreases the bradykinesia of shoulder movements.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Participant)

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Clinical diagnosis of Parkinson Disease

Exclusion Criteria

  • Patients with a limitation in the shoulder range of motion necessary to perform pointing movements

Outcomes

Primary Outcomes

3D kinematic movement parameters and upper limb muscles electromyographic activation

Time Frame: Participants will be followed for the duration of the clinical test (2 weeks)

Secondary Outcomes

  • Unified Parkinson's Disease Rating Scale (UPDRS)(Participants will be followed for the duration of the clinical test (2 weeks))

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Ana Bengoetxea

Assistant Professor

Université Libre de Bruxelles

Study Sites (2)

Loading locations...

Similar Trials